ArticleAntimicrobial agents and chemotherapy2014
Time-kill assay and Etest evaluation for synergy with polymyxin B and fluconazole against Candida glabrata.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- On the mode of anti-Future science OA · 2026Article
- Development and in vitro evaluation of teicoplanin PEGylated (TEC-PEGylated) niosomes for antimicrobial and anti-biofilm activity against vancomycin-intermediate Staphylococcus aureus (VISA).BMC biotechnology · 2026Article
- Peptide-based antimicrobial effect against carbapenem-resistantFrontiers in pharmacology · 2026Article
- Evaluation of the Synergistic Activity of Antimicrobial Peptidomimetics or Colistin Sulphate with Conventional Antifungals Against Yeasts of Medical Importance.Journal of fungi (Basel, Switzerland) · 2025Article
- In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates.European journal of medical research · 2024Article
- In silico molecular modelling studies and antibiofilm efficacy of shikonin against Candida albicans: mechanistic insight.Archives of microbiology · 2023Article
- High-Resolution Bacterial Cytological Profiling Reveals Intrapopulation Morphological Variations upon Antibiotic Exposure.Antimicrobial agents and chemotherapy · 2023Article
- Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- Combination Therapy to Treat Fungal Biofilm-Based Infections.International journal of molecular sciences · 2020Review
- Pathogenesis and Clinical Relevance ofFrontiers in microbiology · 2020Review
- Antifungal Susceptibly Testing by Concentration Gradient Strip Etest Method for Fungal Isolates: A Review.Journal of fungi (Basel, Switzerland) · 2019Review
- Article
- In vitro polymyxin activity against clinical multidrug-resistant fungi.Antimicrobial resistance and infection control · 2019Article
- The Synergism of the Small Molecule ENOblock and Fluconazole Against Fluconazole-ResistantFrontiers in microbiology · 2019Article
- Article
- Kinase Inhibitors that Increase the Sensitivity of Methicillin Resistant Staphylococcus aureus to β-Lactam Antibiotics.Pathogens (Basel, Switzerland) · 2015Article
- Recent publications by ochsner authors.Ochsner journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluconazole-resistant Candida glabrata is an emerging pathogen that causes fungemia. Polymyxin B, a last-resort antibiotic used to treat multidrug-resistant Gram-negative bacterial infections, has been found to possess in vitro fungicidal activity and showed synergy with fluconazole against a single strain of C. glabrata. Since both agents may be used simultaneously in intensive care unit (ICU) patients, this study was performed to test for possible synergy of this combination against 35 C. glabrata blood isolates, using 2 methods: a time-kill assay and an experimental MIC-MIC Etest method. Thirty-five genetically unique C. glabrata bloodstream isolates were collected from 2009 to 2011, identified using an API 20C system, and genotyped by repetitive sequence-based PCR (rep-PCR). MICs were determined by Etest and broth microdilution methods. Synergy testing was performed using a modified bacterial Etest synergy method and time-kill assay, with final results read at 24 h. The Etest method showed synergy against 19/35 (54%) isolates; the time-kill assay showed synergy against 21/35 (60%) isolates. Isolates not showing drug synergy had an indifferent status. Concordance between methods was 60%. In vitro synergy of polymyxin B and fluconazole against the majority of C. glabrata isolates was demonstrated by both methods. The bacterial Etest synergy method adapted well when used with C. glabrata. Etest was easier to perform than time-kill assay and may be found to be an acceptable alternative to time-kill assay with antifungals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.